PHC Holdings (6523) · InitiativeAdvanced
Technology Development for In-Line Monitoring and Cell and Gene Therapies
First written in FY2025. 1 of 2 entries say "Advanced", first in FY2026. Latest entry: FY2026.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Development of Cell Culture Equipment and Tools for Regenerative Medicine and Drug DiscoveryA theme 4 companies write about · 0 as a headwind · 5 as a tailwind
0 other companies' latest entry also says "Advanced".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2026AdvancedAnnual report
「As a new product related to the cell and gene therapy field, the Company internally developed LiCellGrow (リセルグロー), an automated cell culture system that visualises continuous metabolic changes in cells in real time and automatically controls the culture process based on measurement results, and began selling it on 2 March 2026.」
Following the launch of LiCellMo in the previous fiscal year, the Company launched LiCellGrow, which provides automated culture control, extending its In-Line monitoring technology to products for cell and gene therapies. - FY2025First statedAnnual report
「The Company began selling LiCellMo (リセルモ), a live-cell metabolic analysis instrument for research that visualises metabolic changes in cultured cells in real time, in Japan from September and overseas from October.」
The Company launched LiCellMo using In-Line monitoring based on blood glucose sensor technology and is working to improve the efficiency and quality of cell and gene therapy culture processes through the demonstration of a LiCellGrow prototype and joint research with CCRM.